DelveInsight’s ’Liquid Biopsy in Cancer Diagnostics Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of liquid biopsy in cancer diagnostics and the historical and forecasted liquid biopsy in cancer diagnostics market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.

The Liquid Biopsy in Cancer Diagnostics market report provides an overview of liquid biopsy in cancer diagnostics, applications of liquid biopsy in cancer diagnostics as well as its PEST Analysis. Additionally, the report provides insight on the liquid biopsy in cancer diagnostics market share of the individual liquid biopsy in cancer diagnostics, current and forecasted liquid biopsy in cancer diagnostics market size from 2018 to 2026, segmented by seven major markets. The report also covers the market drivers, market barriers and unmet needs to curate the best of opportunities and assesses underlying potential of the market.

Liquid Biopsy in Cancer Diagnostics Overview
Liquid biopsy is a method used to detect specific mutations in cell-free, circulating tumor DNA (ctDNA) from biofluids, such as plasma, urine, cerebrospinal fluid, and serum. Researchers around the world are actively investigating the use of ctDNA as a biomarker for profiling tumors, monitoring the effectiveness of therapies, assessing the clonal evolution of tumor cell populations, identifying resistance mechanisms, detecting early disease, and measuring minimal residual disease. Regardless of the specific use, liquid biopsy has the benefit of being non-invasive, and thus allowing samples to be easily collected for serial assessments. Mutation detection in liquid biopsy, however, is challenged by the extremely low fraction of ctDNA in the cell-free DNA (cfDNA) samples, making accurate detection of rare mutations difficult.

Study Period: 2018–2026
Geography Covered

  • The US
  • EU5 (Germany, France, Spain, Italy, and the United Kingdom)
  • Japan



List of Companies:
Guardant Health, Qiagen, F. Hoffmann-La Roche AG, Inviata, ArcherDx, Bio-Techne., Resolution Bioscience & LabCorp., Personal Genome Diagnostics., Helio Health, Lucence, Foundation medicine Inc.., Biocept, Sysmex Corporation, Veridex LLC and Biodesix, among others.


This segment of the report provides a brief competitive analysis of liquid biopsy in cancer diagnostics, to help understand the competition in the market. It gives a comparative understanding of the products based on types.

Liquid Biopsy in Cancer Diagnostics: Market Segmentation
By Sample Type

  • Blood
  • Urine



By Technique

  • Next Generation Sequencing
  • Polymerase Chain Reaction



By Biomarker Type

  • Circulating tumor DNA (ctDNA)
  • Circulating free DNA (cfDNA)
  • Circulating tumor cells (CTCs)
  • Others



By End User

  • Hospitals
  • Clinics
  • Diagnostic Centers



Liquid Biopsy in Cancer Diagnostics: Market Dynamics
Market Drivers

  • Increase in disposable income which has led to more people opting for aesthetic surgeries.
  • The rising number of cases of breast cancer worldwide which is a contributing factor in the growing demand for liquid biopsy in cancer diagnostics.



Market Barriers

  • High cost of surgeries and post-surgical complications.
  • Adverse events and product recalls.



Liquid Biopsy in Cancer Diagnostics: Market Analysis
This segment illustrates the market of liquid biopsy in cancer diagnostics across the 7MM and how the market is expected to rise in the study period (2018 to 2026), at a significant CAGR.

KOL Views
To keep up with the market trends, we take KOLs and SME’s opinion working in liquid biopsy in cancer diagnostics domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or liquid biopsy in cancer diagnostics market trend. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

  • The report covers the descriptive overview of liquid biopsy in cancer diagnostics, explaining its applications, advantages, and limitations, etc.
  • Additionally, an all-inclusive account of the currently available liquid biopsy in cancer diagnostics is provided, which will have an impact on the future market of liquid biopsy in cancer diagnostics.
  • A detailed review of liquid biopsy in cancer diagnostics market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the liquid biopsy in cancer diagnostics market.





Report Highlights

  • The report covers descriptive overview of the liquid biopsy in cancer diagnostics, explaining its applications, working mechanism, etc.
  • The report is a comprehensive account of marketed devices present in the liquid biopsy in cancer diagnostics market.
  • The report also reviews the detailed historical and forecasted liquid biopsy in cancer diagnostics market, including assessing the outreach in 7 MM.
  • The report helps in developing business strategies by understanding trends shaping and driving the liquid biopsy in cancer diagnostics market.




Liquid Biopsy in Cancer Diagnostics Report Key Strengths

  • 6 Years Forecast
  • 7MM Coverage
  • Competitive Landscape
  • PEST Analysis
  • Market Size




Liquid Biopsy in Cancer Diagnostics Report Assessment

  • Marketed Product profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
  • Market Forecast
  • KOL’S views




Key Questions
Market Insights:

  • What was the liquid biopsy in cancer diagnostics market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the liquid biopsy in cancer diagnostics total market size as well as market size by devices across the 7MM during the forecast period (2018–2026)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest liquid biopsy in cancer diagnostics market size during the forecast period (2018–2026)?
  • At what CAGR, the liquid biopsy in cancer diagnostics market is expected to grow in the 7MM during the forecast period (2018–2026)?
  • What will be the liquid biopsy in cancer diagnostics market outlook across the 7MM during the forecast period (2018–2026)?
  • What will be the liquid biopsy in cancer diagnostics market growth till 2026 and what will be the resultant market size in the year 2026?
  • How will the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?



Competitive Landscape:

  • What are the current devices available in the liquid biopsy in cancer diagnostics market?
  • What are the liquid biopsy in cancer diagnostics available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
  • How many key players are developing liquid biopsy in cancer diagnostics?
  • What are the key collaborations (Industry–Industry), mergers and acquisitions, licensing activities related to the liquid biopsy in cancer diagnostics?
  • What are the key designations that have been granted for the current liquid biopsy in cancer diagnostics?
  • What are the 7MM countries historical and forecasted market of liquid biopsy in cancer diagnostics?